Laura McDowell
Revolution Medicines (United States)(US)
Publications by Year
Research Areas
Cholinesterase and Neurodegenerative Diseases, Phosphodiesterase function and regulation, Chemical synthesis and alkaloids, Biochemical and Molecular Research, Ubiquitin and proteasome pathways
Most-Cited Works
- → Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers(2023)61 cited
- → The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations(2012)57 cited
- → Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors(2012)55 cited
- → Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia(2011)52 cited
- → Cloning and Functional Characterization of an NAD + -Dependent DNA Ligase from Staphylococcus aureus(2001)51 cited
- → Structure of a small‐molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site(2008)50 cited
- → Characterization of substrate binding and catalysis in the potential antibacterial target N‐acetylglucosamine‐1‐phosphate uridyltransferase (GlmU)(2007)43 cited
- → Identification of Multiple 5-HT4Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease(2012)42 cited
- → Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers(2021)33 cited
- → Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor(2017)32 cited